Cargando…

Possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy

BACKGROUND: Although patients with moderate intellectual disability (ID) are known to have higher rates of being overweight and obese than those without ID, there are no current data regarding the relationship between ID and weight gain in epilepsy patients treated with valproic acid (VPA). PATIENTS...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanamachi, Yukiko, Saruwatari, Junji, Noai, Madoka, Kamihashi, Ryoko, Soraoka, Hiromi, Yoshimori, Yuki, Ogusu, Naoki, Oniki, Kentaro, Yasui-Furukori, Norio, Ishitsu, Takateru, Nakagawa, Kazuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397927/
https://www.ncbi.nlm.nih.gov/pubmed/25897238
http://dx.doi.org/10.2147/NDT.S80898
_version_ 1782366772014350336
author Tanamachi, Yukiko
Saruwatari, Junji
Noai, Madoka
Kamihashi, Ryoko
Soraoka, Hiromi
Yoshimori, Yuki
Ogusu, Naoki
Oniki, Kentaro
Yasui-Furukori, Norio
Ishitsu, Takateru
Nakagawa, Kazuko
author_facet Tanamachi, Yukiko
Saruwatari, Junji
Noai, Madoka
Kamihashi, Ryoko
Soraoka, Hiromi
Yoshimori, Yuki
Ogusu, Naoki
Oniki, Kentaro
Yasui-Furukori, Norio
Ishitsu, Takateru
Nakagawa, Kazuko
author_sort Tanamachi, Yukiko
collection PubMed
description BACKGROUND: Although patients with moderate intellectual disability (ID) are known to have higher rates of being overweight and obese than those without ID, there are no current data regarding the relationship between ID and weight gain in epilepsy patients treated with valproic acid (VPA). PATIENTS AND METHODS: The possible association between moderate ID and an overweight status at the time of initiation of VPA therapy (baseline) was investigated using a logistic regression analysis in 143 patients with epilepsy. Among the 119 nonoverweight patients at baseline, the longitudinal association between moderate ID and the weight status during VPA therapy was retrospectively examined using a Cox hazards regression analysis and the generalized estimating equations approach, while also paying careful attention to associations with other patient characteristics. RESULTS: The proportion of patients with moderate ID was 52.4% among the 143 study subjects. The presence of moderate ID was not associated with an overweight status at baseline (P=0.762). Among the nonoverweight patients at baseline, 16 subjects were newly diagnosed as being overweight during treatment with VPA (3.6±2.1 years). The presence of moderate ID was significantly associated with the incidence of an overweight status after starting VPA therapy (adjusted hazard ratio =6.72, P=0.007). The patient age at baseline and treatment with co-administered carbamazepine, clobazam, and zonisamide significantly influenced the degree of weight fluctuation during VPA therapy among the patients with moderate ID (P<0.001, P<0.001, P=0.002, and P=0.028, respectively), whereas only patient age at baseline affected this parameter among the patients without moderate ID (P=0.022). CONCLUSION: The present findings suggest that the weight status should be carefully monitored in VPA-treated patients with moderate ID, especially those receiving other co-administered antiepileptic drugs that facilitate weight gain, such as carbamazepine.
format Online
Article
Text
id pubmed-4397927
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-43979272015-04-20 Possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy Tanamachi, Yukiko Saruwatari, Junji Noai, Madoka Kamihashi, Ryoko Soraoka, Hiromi Yoshimori, Yuki Ogusu, Naoki Oniki, Kentaro Yasui-Furukori, Norio Ishitsu, Takateru Nakagawa, Kazuko Neuropsychiatr Dis Treat Original Research BACKGROUND: Although patients with moderate intellectual disability (ID) are known to have higher rates of being overweight and obese than those without ID, there are no current data regarding the relationship between ID and weight gain in epilepsy patients treated with valproic acid (VPA). PATIENTS AND METHODS: The possible association between moderate ID and an overweight status at the time of initiation of VPA therapy (baseline) was investigated using a logistic regression analysis in 143 patients with epilepsy. Among the 119 nonoverweight patients at baseline, the longitudinal association between moderate ID and the weight status during VPA therapy was retrospectively examined using a Cox hazards regression analysis and the generalized estimating equations approach, while also paying careful attention to associations with other patient characteristics. RESULTS: The proportion of patients with moderate ID was 52.4% among the 143 study subjects. The presence of moderate ID was not associated with an overweight status at baseline (P=0.762). Among the nonoverweight patients at baseline, 16 subjects were newly diagnosed as being overweight during treatment with VPA (3.6±2.1 years). The presence of moderate ID was significantly associated with the incidence of an overweight status after starting VPA therapy (adjusted hazard ratio =6.72, P=0.007). The patient age at baseline and treatment with co-administered carbamazepine, clobazam, and zonisamide significantly influenced the degree of weight fluctuation during VPA therapy among the patients with moderate ID (P<0.001, P<0.001, P=0.002, and P=0.028, respectively), whereas only patient age at baseline affected this parameter among the patients without moderate ID (P=0.022). CONCLUSION: The present findings suggest that the weight status should be carefully monitored in VPA-treated patients with moderate ID, especially those receiving other co-administered antiepileptic drugs that facilitate weight gain, such as carbamazepine. Dove Medical Press 2015-04-07 /pmc/articles/PMC4397927/ /pubmed/25897238 http://dx.doi.org/10.2147/NDT.S80898 Text en © 2015 Tanamachi et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Tanamachi, Yukiko
Saruwatari, Junji
Noai, Madoka
Kamihashi, Ryoko
Soraoka, Hiromi
Yoshimori, Yuki
Ogusu, Naoki
Oniki, Kentaro
Yasui-Furukori, Norio
Ishitsu, Takateru
Nakagawa, Kazuko
Possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy
title Possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy
title_full Possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy
title_fullStr Possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy
title_full_unstemmed Possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy
title_short Possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy
title_sort possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397927/
https://www.ncbi.nlm.nih.gov/pubmed/25897238
http://dx.doi.org/10.2147/NDT.S80898
work_keys_str_mv AT tanamachiyukiko possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy
AT saruwatarijunji possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy
AT noaimadoka possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy
AT kamihashiryoko possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy
AT soraokahiromi possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy
AT yoshimoriyuki possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy
AT ogusunaoki possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy
AT onikikentaro possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy
AT yasuifurukorinorio possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy
AT ishitsutakateru possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy
AT nakagawakazuko possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy